Hexarelin (Examorelin) dosage in published studies and labels

These are the doses used for Hexarelin (Examorelin) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: September 5, 2026

Studied regimens and sources

Hexarelin has a published human dose-response study: intravenous doses from 0 to 1.0 mcg/kg in healthy adult men, with the growth hormone response reaching a plateau at 1.0 mcg/kg. That study also measured cortisol and prolactin release, which is the finding most often left out when hexarelin is discussed. No product is approved and no repeated-dosing regimen is established.

Limited Human Evidence

Dosage evidence summary for Hexarelin (Examorelin)
Human dosing established	Yes
Studied dose range	0.125–1.0 mcg/kg intravenously (weight-based)
Route	Intravenous
Frequency	Single doses in the published dose-response work
Duration studied	Acute pharmacology protocol
Evidence level	Limited Human Evidence
Last reviewed	2026-09-05

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Hexarelin (Examorelin), one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
Dose-response study in healthy men (1996)Clinical trial · Human dose-response pharmacology study	Healthy adult males	0 to 1.0 mcg/kg; plateau GH response at 1.0 mcg/kg; 0.125 mcg/kg used as the low dose in combination with GHRH(1-29)-NH2 1.0 mcg/kg	Intravenous	Single dose per level	Acute	Growth hormone, cortisol and prolactin release	Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab. 1996.

Where sources disagree

Published human dosing is weight-based and intravenous — 1.0 mcg/kg is roughly 70 mcg for a 70 kg adult. Hexarelin is sold with fixed subcutaneous protocols commonly quoted at 100–200 mcg two or three times daily, which is both a higher dose and a different route from anything published.
The same dose-response study that established hexarelin's growth hormone effect also reported cortisol and prolactin release. Secondary sources routinely cite the growth hormone finding and omit the other two, which come from the identical experiment.
The published work is acute and single-dose. Desensitisation with repeated administration is a recognised issue for growth hormone secretagogues and is not addressed by a single-dose study.